Compare AANJANEYA LIFECARE with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS VENUS REMEDIES DR. DATSONS LABS/
VENUS REMEDIES
 
P/E (TTM) x -10.9 -9.9 - View Chart
P/BV x 0.2 0.7 24.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   VENUS REMEDIES
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
VENUS REMEDIES
Mar-18
DR. DATSONS LABS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs126126 99.8%   
Low Rs3161 50.6%   
Sales per share (Unadj.) Rs133.0301.8 44.1%  
Earnings per share (Unadj.) Rs0.2-24.9 -0.6%  
Cash flow per share (Unadj.) Rs6.62.5 259.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.8293.3 43.9%  
Shares outstanding (eoy) m31.6612.34 256.6%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.60.3 189.9%   
Avg P/E ratio x516.1-3.8 -13,728.5%  
P/CF ratio (eoy) x11.836.7 32.2%  
Price / Book Value ratio x0.60.3 190.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,4771,154 214.7%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m56393 14.2%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m4,2113,724 113.1%  
Other income Rs m7923 349.8%   
Total revenues Rs m4,2893,747 114.5%   
Gross profit Rs m569395 144.0%  
Depreciation Rs m204338 60.4%   
Interest Rs m430354 121.4%   
Profit before tax Rs m13-275 -4.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m632 19.3%   
Profit after tax Rs m5-307 -1.6%  
Gross profit margin %13.510.6 127.4%  
Effective tax rate %48.0-11.5 -418.5%   
Net profit margin %0.1-8.2 -1.4%  
BALANCE SHEET DATA
Current assets Rs m6,8522,638 259.8%   
Current liabilities Rs m6,7112,305 291.2%   
Net working cap to sales %3.38.9 37.4%  
Current ratio x1.01.1 89.2%  
Inventory Days Days161135 118.8%  
Debtors Days Days31846 687.4%  
Net fixed assets Rs m3,6734,871 75.4%   
Share capital Rs m317123 256.6%   
"Free" reserves Rs m3,7613,496 107.6%   
Net worth Rs m4,0783,619 112.7%   
Long term debt Rs m1,6711,374 121.6%   
Total assets Rs m12,6337,509 168.2%  
Interest coverage x1.00.2 461.7%   
Debt to equity ratio x0.40.4 107.9%  
Sales to assets ratio x0.30.5 67.2%   
Return on assets %3.40.6 545.5%  
Return on equity %0.1-8.5 -1.4%  
Return on capital %7.71.6 485.0%  
Exports to sales %22.90-   
Imports to sales %14.313.9 103.1%   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602517 116.5%   
Fx inflow Rs m9640-   
Fx outflow Rs m607517 117.5%   
Net fx Rs m357-517 -69.1%   
CASH FLOW
From Operations Rs m1,345514 261.4%  
From Investments Rs m-2,256-123 1,832.3%  
From Financial Activity Rs m-1,200-387 309.9%  
Net Cashflow Rs m-2,1114 -50,254.8%  

Share Holding

Indian Promoters % 4.5 32.9 13.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.2 -  
FIIs % 1.4 0.6 232.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 66.4 141.7%  
Shareholders   20,807 20,121 103.4%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  AJANTA PHARMA  UNICHEM LAB  

Compare DR. DATSONS LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS